The Life Sciences Report: The Patient Protection and Affordable Care Act (ACA/Obamacare) affects medtech both directly and indirectly. From that perspective, is the ACA an obvious obstacle to growth right now? Or is there potential upside from increased volumes of procedures?
William Plovanic: I would not expect the Affordable Care Act to bring incremental patients into the mix. I don’t think any investors or device company executives believe this will be a benefit to device companies in general—or at all. It’s a revenue stream for the government, and companies aren’t going to … [visit site to read more]
Similar posts:- What Moves Biotech Stocks? Ed Arce Has Answers. The Life Sciences Report: Your experience is very broad. Just...
- Top Medtech Analyst Points to Post-Obamacare Opportunities The Life Sciences Report: You have worked in the big...
- Choose Medical Technology Stocks Carefully: William Plovanic The Life Sciences Report: What is the general feeling of...
